


## MRL-871

<b>Cat. No.:</b>	HY-119464		
<b>CAS No.:</b>	1392809-08-3		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>12</sub> ClF <sub>3</sub> N <sub>2</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	444.79		
<b>Target:</b>	ROR		
<b>Pathway:</b>	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 25 mg/mL (56.21 mM; ultrasonic and warming and heat to 60°C)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.2483 mL	11.2413 mL	22.4825 mL
	5 mM	0.4497 mL	2.2483 mL	4.4965 mL
	10 mM	0.2248 mL	1.1241 mL	2.2483 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

MRL-871 (compound 3) is a potent and allosteric retinoic acid receptor-related orphan receptor  $\gamma$ t (ROR $\gamma$ t) inverse agonists with an IC<sub>50</sub> of 12.7 nM. MRL-871 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells<sup>[1]</sup>.

#### In Vitro

MRL-871 (compound 3; 10  $\mu$ M, 24h) significantly reduces IL-17a mRNA expression 48-fold in EL4 cells<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Meijer FA, et, al. Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor  $\gamma$ t (ROR $\gamma$ t) Inverse Agonists. J Med Chem. 2020 Jan 9;63(1):241-259.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA